MELT PHARMACEUTICALS INC
Business Summary
Melt Pharmaceuticals Inc is a United States-based clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of non-opioid, non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its product candidate pipeline consists of: MELT-300, is a lead product candidate, which is a fixed dose combination of midazolam and ketamine in a fast-dissolving tablet that is administered sublingually for procedural sedation and analgesia during cataract surgery; MELT-210, which is a fixed dose of midazolam in a fast-dissolving tablet that is administered sublingually for procedural sedation for short duration procedures; and MELT-400, which is a fixed dose of ketamine in a fast-dissolving tablet that is administered sublingually for short-term or acute pain.
Country of Incorporation
United States of America
Incorporation Date
2019-01-30
Business Sector
Pharmaceuticals & Medical Research
Company Address
5511 Virginia Way, Suite 300
Get access to the below data and more business development tools by signing up for the MENA Company Data product.
- Ownership details
- Corporate structure
- Business classification
- Officers & Directors contact details
- Full company contact details
Multiply your reach by contributing your content to LSEG
LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.NEWS ON THIS COMPANY
TOP PICKS
MOST READ
MOST WATCHED
MOST POPULAR
1.
2.
3.
4.
5.
